Hopes that AstraZeneca’s legal dispute with European Union on the deliveries of coronavirus vaccines in the coming weeks will be settled by a high-ranking official, possibly putting an end to the dispute that has plagued the pharmaceutical industry and Brussels this year.
The company is in talks with the EU, said in a press conference Rudd Dober, executive vice president of the biopharmaceutical company. “We hope to have a settlement in the coming weeks,” he said, without elaborating.
According to the Athenian-Macedonian News Agency, the pharmaceutical industry announced today that sales of its COVID-19 vaccine reached $ 1.17 billion in the first half of the year and increased forecasts for the future.
This number corresponds to the delivery of approximately 319 billion installments worldwide, which it sells at a cost price, without profit. Sales represent $ 572 million in Europe and $ 455 million in emerging countries, according to a statement from the Swedish-British group.
The group’s turnover during this period increased by 20% year-on-year to $ 15.5 billion and the group’s net profit by 40% to $ 2.1 billion.
The group claims that progress in its growing product portfolio and the recent acquisition of Alexion support its further growth in the long run.
THE AstraZeneca It also raises forecasts for year-end results mainly to reflect the contribution of Alexion, whose acquisition has just been completed, but without taking into account sales of the COVID-19 vaccine.
“AstraZeneca has created a new period of strong growth thanks to a solid performance in all areas and in all pathologies”, mainly in oncology, said the general manager of the company Pascal Sorio.
The Swedish-British pharmaceutical group announced in mid-July that it had secured UK approval for a $ 39 billion acquisition of rare diseases by US biotechnology company Alexion.
“AstraZeneca continues to recognize the risks and significant uncertainties associated with the effects of COVID-19, including the potential impact of new antiviral drugs currently in clinical development.”
Problems
The preparation of the AstraZeneca COVID-19 vaccine, one of the first on the market, although the group did not have a large presence in the vaccines until then, was followed by many problems for the group, mainly doubts about its effectiveness and concerns after blood clot incidents. -although very rare in relation to the millions of doses that have been administered. Added to this was a dispute with Brussels over vaccine deliveries.
Pascal Sorio also said that AstraZeneca is still planning to seek approval for its COVID-19 vaccine in the US, although the process is taking longer than expected because (the vaccine) could still be used there in the future.
“The simple answer is that this is an important vaccine. “And we believe it can play a role in the future, so we want to apply and get approval for it,” he said, when asked why the pharmaceutical industry is seeking approval, although the country has enough supplies to vaccinate its population without it. .
Sorio said the company does not need US approval to boost the credibility of the Vaxzervia vaccine worldwide. Some 170 countries have approved it before use.
“We just want to make sure it is ready to use when needed,” he said.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
